Vertex Lifted Its Revenue Outlook As Alyftrek Picked Up Steam

Vertex Pharmaceuticals increased its full-year revenue forecast to $13.1-13.2 billion, driven by strong performance from its new cystic fibrosis drug, Alyftrek. The company's second-quarter revenue reached $3.33 billion, exceeding analyst estimates, with Alyftrek contributing significantly. A new, higher forecast is anticipated after the completion of Vertex's $10 billion acquisition of Crinetics, which is expected to provide insight into the company's diversification strategy beyond cystic fibrosis.